Ananda Developments PLC Research Round Up
23 June 2023 - 5:30PM
RNS Non-Regulatory
TIDMANA
Ananda Developments PLC
23 June 2023
ANANDA DEVELOPMENTS PLC
Ananda's ambition is to be a leading provider of high-quality
cannabinoid medicines for the treatment of complex, chronic
inflammatory pain conditions in the UK and for international
markets.
Medical Cannabis Research Roundup
Issue Twenty
Summary:
This month we have seen papers on anti-tumour mechanisms of CBD
- including a list of 27 target cells and cytokines - more efficacy
in epilepsy, beneficial effects of CBD for dementia sufferers, and
interesting articles on the role of the endocannabinoid system
(ECS) in axon regeneration and its involvement in the gut
microbiome axis!
Most of this is either basic science, as get to better
understand some of the mechanisms of the ECS and the activity of
phytocannabinoids both within and without the basic ECS, or
evidence from observational trials - most calling for more
randomised controlled trials.
Two that we thought particularly interesting are summarised
below - the benefits of a low dose CBD regime on dementia sufferers
and a positive paper on medical cannabis in the UK for fibromyalgia
- showing the increase in quality of life over a 12-month
period.
CBD can be beneficial for behavioural symptoms of dementia.
One of the main problems in caring for dementia patients is
their level of behavioural disturbance, which causes distress and
fatigue for carers and family and leads to early
institutionalisation for the patients.
A study in Greece demonstrated that a small dose of CBD oil
sublingually - up to 10mg/day via a 3% CBD oil - had a significant
effect on the level of behavioural disturbance.
Scores of Neuropsychiatric Inventory which measures 12 areas of
behavioural and psychological symptoms of dementia (BPSD) -
agitation, aberrant motor behaviour, anxiety, elation,
irritability, depression, apathy, disinhibition, delusions,
hallucinations, sleep, and appetite changes - went from an average
of 60 to 15 over the six-month period of the trial.
60 indicates a very high level of behavioural disturbance while
15 is a low to moderate of behavioural disturbance.
The MMSE score s which measures cognitive function did not
change - unsurprising, as these levels indicate neuronal death.
Not only can CBD make life better for patients and carers but it
would likely lead to much later institutionalisation of patients
decreasing cost and distress.
Not only can CBD make life better for patients and carers but it
would likely lead to much later institutionalization of patients
decreasing cost and distress.
The Effect of Cannabidiol 3% on Neuropsychiatric Symptoms in
Dementia - Six-Month Follow-Up
https://www.tandfonline.com/doi/full/10.1080/07317115.2023.2209563
Treatment with cannabis-based medicinal products (CBMPs )
improves quality of life scores significantly for Fibromyalgia.
An analysis of the clinical outcomes for patients taking medical
cannabis (found on the UK Medical Cannabis Registry ) shows
improvements in fibromyalgia symptoms as well as those for sleep,
anxiety and health-related quality of life.
All five domains of the EQ-5D-5L showed statistically
significant improvement in 1-, 3-, and 6-month follow-ups.
The study stated that there is good cause for randomised
controlled trials to be undertaken to better evidence the efficacy
and safety of CBMPs.
Assessment of clinical outcomes in patients with fibromyalgia:
Analysis from the UK Medical Cannabis Registry
https://pubmed.ncbi.nlm.nih.gov/37199833/
The Directors of the Company accept responsibility for the
contents of this announcement.
ANANDA DEVELOPMENTS PLC +44 (0)7463 686 497
Chief Executive Officer
Melissa Sturgess
Investor Relations
Jeremy Sturgess-Smith
SP ANGEL CORPORATE FINANCE LLP +44 (0)20 3470 0470
Corporate Finance
Richard Morrison
Harry Davies-Ball
Corporate Broking
Abigail Wayne
Rob Rees
About Ananda Developments
Ananda is an AQSE-listed medical cannabis company with UK-based
operations to grow and provide carbon zero, consistent, cannabinoid
medicines for the UK and international markets.
For more information, please visit:
https://anandadevelopments.com/
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAGCGDLGSDDGXD
(END) Dow Jones Newswires
June 23, 2023 03:30 ET (07:30 GMT)
Ananda Developments (AQSE:ANA)
Historical Stock Chart
From Apr 2024 to May 2024
Ananda Developments (AQSE:ANA)
Historical Stock Chart
From May 2023 to May 2024